| Trial ID: | L4415 |
| Source ID: | NCT00823849
|
| Associated Drug: |
Cilostazol
|
| Title: |
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans
|
| Interventions: |
DRUG: Cilostazol|DRUG: Probucol|DRUG: Cilostazol+Probucol|OTHER: Control Group
|
| Outcome Measures: |
Primary: Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment., 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Otsuka Beijing Research Institute
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-10
|
| Completion Date: |
2010-03
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-27
|
| Locations: |
Peking University First Hospital, Beijing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00823849
|
